Public drug insurance, moral hazard and children's use of mental health medication: Latent mental health risk-specific responses to lower out-of-pocket treatment costs

Health Econ. 2023 Feb;32(2):518-538. doi: 10.1002/hec.4631. Epub 2022 Nov 21.

Abstract

Studies have shown that reducing out-of-pocket costs can lead to higher medication initiation rates in childhood. Whether the cost of such initiatives is inflated by moral hazard issues remains a question of concern. This paper looks to the implementation of a public drug insurance program in Québec, Canada, to investigate potential low-benefit consumption in children. Using a nationally representative longitudinal sample, we harness machine learning techniques to predict a child's risk of developing a mental health disorder. Using difference-in-differences analyses, we then assess the impact of the drug program on children's mental health medication uptake across the distribution of predicted mental health risk. Beyond showing that eliminating out-of-pocket costs led to a 3 percentage point increase in mental health drug uptake, we show that demand responses are concentrated in the top two deciles of risk for developing mental health disorders. These higher-risk children increase take-up of mental health drugs by 7-8 percentage points. We find even stronger effects for stimulants (8-11 percentage point increases among the highest risk children). Our results suggest that reductions in out-of-pocket costs could achieve better uptake of mental health medications, without inducing substantial low-benefit care among lower-risk children.

Keywords: children health; mental health; out-of-pocket costs; prescription drugs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child
  • Drug Costs
  • Health Care Costs
  • Health Expenditures*
  • Humans
  • Insurance, Health
  • Insurance, Pharmaceutical Services
  • Mental Health*
  • Morals

Grants and funding